Sapanisertib
- Generic Name
- Sapanisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15N7O
- CAS Number
- 1224844-38-5
- Unique Ingredient Identifier
- JGH0DF1U03
- Background
Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
Phase 1
Terminated
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT02133183
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02091531
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02049957
- Locations
- 🇺🇸
Henry Ford Medical Center, Novi, Michigan, United States
🇺🇸Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
🇫🇷Institut Sainte Catherine, Avignon, Vaculuse, France
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
Phase 1
Completed
- Conditions
- Advanced Nonhematologic Malignancies
- Interventions
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01899053
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid MalignanciesHematologic Malignancies
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01351350
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Phase 1
Completed
- Conditions
- Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01118689
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT01058707
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath